Abstract
Resolving chromatin remodeling-linked gene expression changes at cell type resolution is important for understanding disease states. We describe MAGICAL, a hierarchical Bayesian approach that leverages paired scRNA-seq and scATAC-seq data from different conditions to map disease-associated transcription factors, chromatin sites, and genes as regulatory circuits. By simultaneously modeling signal variation across cells and conditions in both omics data types, MAGICAL achieved high accuracy on circuit inference. We applied MAGICAL to study Staphylococcus aureus sepsis from peripheral blood mononuclear single-cell data that we generated from infected subjects with bloodstream infection and from uninfected controls. MAGICAL identified sepsis-associated regulatory circuits predominantly in CD14 monocytes, known to be activated by bacterial sepsis. We addressed the challenging problem of distinguishing host regulatory circuit responses to methicillin-resistant-(MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) infections. While differential expression analysis failed to show predictive value, MAGICAL identified epigenetic circuit biomarkers that distinguished MRSA from MSSA.
Competing Interest Statement
A.G.L. is a military service member. This work was prepared as part of his official duties. Title 17, US Code 105 provides that copyright protection under this title is not available for any work of the US Government. Title 17, US code 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person official duties. The views expressed in the article are those of the authors and do not necessarily express the official policy and position of the US Navy, the Department of Defense, the US Government, or the institutions affiliated with the authors. V.G.F. reports personal fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, grants from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, Deep Blue, Basilea, Janssen; Royalties from UpToDate, stock options from Valanbio and ArcBio, Honoraria from Infectious Diseases of America for his service as Associate Editor of Clinical Infectious Diseases, and a patent sepsis diagnostics pending. L.C.N. has received consulting fees from work as a scientific advisor for AbbVie, ViiV Healthcare, and Cytodyn and also serves on the Board of Directors of CytoDyn and has financial interests in Ledidi AS, all for work outside of the submitted work. S.C.S. is a founder of GNOMX Corp and serves as chief scientific officer. The remaining authors declare no competing interests.
Funding Statement
We thank the Single-cell and Spatial Technologies team at the Center for Advanced Genomics Technology, Department of Genetics and Genomic Sciences, the Icahn School of Medicine at Mount Sinai for providing the experimental, computational, data resources, and staff expertise. S.C.S was supported by the Defense Advanced Research Projects Agency under contract N6600119C4022. A.G.L. is supported by Defense Health Agency grant 9700130 through the Naval Medical Research Center. O.G.T. is supported by National Institutes of Health under grant R01GM071966 and Simons Foundation under grant 395506. L.C.N. is supported by the National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, and National Institute of Allergy and Infectious Diseases under grant UM1AI164599 and by National Institute on Drug Abuse under grants U01 DA53625 and U01DA058527.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Navy COVID-19 study protocol was approved by the Naval Medical Research Center institutional review board (protocol number NMRC.2020.0006) in compliance with all applicable Federal regulations governing the protection of human subjects. The staphylococcus sepsis protocol was reviewed and approved by the Duke Medical School institutional review board (protocol number Pro00102421).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data availability, figure and format changes.
Data Availability
Data from scRNA-seq and scATAC-seq have been deposited with the GEO repository under accession number GSE220190. All the other data used in this study are publicly available and the URLs are provided in the Data Availability section.
https://github.com/xichensf/magical
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE220190
